Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlphaVax and Wyeth extend partnership
The original agreement, executed in 1998, provided Wyeth with access to certain core alphavirus vector technologies controlled by AlphaVax to develop vaccines for selected infectious diseases. The new
The original agreement, executed in 1998, provided Wyeth with access to certain core alphavirus vector technologies controlled by AlphaVax to develop vaccines for selected infectious diseases. The new
Under the extended agreement, Cystic Fibrosis Foundation Therapeutics (CFFT) will provide an additional $22 million to Vertex for continued research funding through early 2008. The first payment is
The new company was founded by former Shire Laboratories president and CEO Jack Khattar, who will retain his job titles at Supernus. Supernus has been funded by the
Source MDx has the ability to analyze biomarkers from a wide variety of samples including a blood sample, which is less invasive than many current clinical tests such
The research team used novel antisense drugs to interrupt normal Ebola virus replication. The findings could serve as the basis for a new approach to quickly develop virus-specific
In their study appearing in the Journal of Clinical Investigation, Giuseppe Matarese and colleagues from Universita di Napoli suggest that leptin neutralization may be a potential way to
These renewable, three-year, master agreements establish a framework for collaboration on a variety of initiatives across a range of AstraZeneca oncology products and research projects. Specific terms of
Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays and CatalogArrays, including the recently introduced influenza A research microarray. Cold Spring has three
The new Boston offer for Guidant is worth in the region of $24.8 billion which compares with the Johnson & Johnson offer of $68.06 per share representing a
SB-509 is designed to upregulate the expression of the patient’s own vascular endothelial growth factor (VEGF) gene to protect and stimulate the regeneration of peripheral nerve function in